benserazide has been researched along with Sleep Initiation and Maintenance Disorders in 4 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
Sleep Initiation and Maintenance Disorders: Disorders characterized by impairment of the ability to initiate or maintain sleep. This may occur as a primary disorder or in association with another medical or psychiatric condition.
Excerpt | Relevance | Reference |
---|---|---|
"Temazepam was consistently less potent than chlormethiazole on tests of drowsiness and psychomotor performance." | 2.67 | A single-dose study of the pharmacodynamic effects of chlormethiazole, temazepam and placebo in elderly parkinsonian patients. ( Ashwood, TJ; Bateman, DN; Tulloch, JA; Woodhouse, KW, 1991) |
"Sixteen patients with symptoms of restless legs syndrome and resulting insomnia are included in this study." | 2.66 | Restless legs syndrome treatment with dopaminergic drugs. ( Akpinar, S, 1987) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (50.00) | 18.7374 |
1990's | 2 (50.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lauerma, H | 1 |
Tulloch, JA | 1 |
Ashwood, TJ | 1 |
Bateman, DN | 1 |
Woodhouse, KW | 1 |
Birkmayer, W | 1 |
Akpinar, S | 1 |
2 trials available for benserazide and Sleep Initiation and Maintenance Disorders
Article | Year |
---|---|
A single-dose study of the pharmacodynamic effects of chlormethiazole, temazepam and placebo in elderly parkinsonian patients.
Topics: Aged; Benserazide; Carbidopa; Chlormethiazole; Double-Blind Method; Drug Therapy, Combination; Femal | 1991 |
Restless legs syndrome treatment with dopaminergic drugs.
Topics: Adult; Aged; Benserazide; Bromocriptine; Clinical Trials as Topic; Double-Blind Method; Female; Huma | 1987 |
2 other studies available for benserazide and Sleep Initiation and Maintenance Disorders
Article | Year |
---|---|
Nocturnal wandering caused by restless legs and short-acting benzodiazepines.
Topics: Anti-Anxiety Agents; Benserazide; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; My | 1991 |
[Therapeutic strategies and tactics in parkinsonism].
Topics: Amantadine; Antidepressive Agents; Antiparkinson Agents; Benserazide; Carbidopa; Depressive Disorder | 1986 |